Tofogliflozin attenuates liver steatosis and fibrosis in non-diabetic non-alcoholic steatohepatitis mice

Abstract Background Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease with increasing global prevalence. Although diabetes is a major factor in NAFLD progression, up to 75% of the patients with NAFLD do not have diabetes. Tofogliflozin (Tofo), a sodium-glucose cotr...

Полное описание

Библиографические подробности

Главные авторы:	Yoshinori Ozono, Hiroshi Kawakami, Hiroshi Hatada, Naomi Uchiyama, Souichiro Ogawa, Keisuke Uchida, Hotaka Tamura, Yuri Komaki, Kenichi Nakamura, Hisayoshi Iwakiri, Satoru Hasuike, Kenji Nagata
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMC 2026-01-01
Серии:	BMC Gastroenterology
Предметы:	NAFLD NASH Tofogliflozin Diabetes CDAHFD
Online-ссылка:	https://doi.org/10.1186/s12876-026-04610-1
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!